Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 1663

1.

Identification of Low-Level Product-Related Variants in Filgrastim Products Presently Available in Highly Regulated Markets.

Hausberger A, Lamanna WC, Hartinger M, Seidl A, Toll H, Holzmann J.

BioDrugs. 2016 Mar 30. [Epub ahead of print]

PMID:
27026103
2.

Rapid formulation assessment of filgrastim therapeutics by a thermal stress test.

Alebouyeh M, Tahzibi A, Yaghoobzadeh S, Zahedy ET, Kiumarsi S, Soltanabad MH, Shahbazi S, Amini H.

Biologicals. 2016 Mar 23. pii: S1045-1056(16)00025-7. doi: 10.1016/j.biologicals.2016.03.001. [Epub ahead of print]

PMID:
27017583
3.

Biosimilars in the management of neutropenia: focus on filgrastim.

Caselli D, Cesaro S, Aricò M.

Biologics. 2016 Feb 18;10:17-22. doi: 10.2147/BTT.S73580. eCollection 2016. Review.

4.

Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.

Pettengell R, Bias P, Mueller U, Lang N.

Support Care Cancer. 2016 Jun;24(6):2677-84. doi: 10.1007/s00520-015-3057-2. Epub 2016 Jan 16.

PMID:
26780505
5.

[Clinical Investigation of the Effects of Filgrastim BS1 on Neutropenia Following Oral Cancer Chemotherapy (TPF Therapy)].

Uchiyama K, Yamada M, Tamate S, Iwasaki K, Mitomo K, Nakayama S.

Gan To Kagaku Ryoho. 2015 Sep;42(9):1073-6. Japanese.

PMID:
26469162
6.

Fully Synthetic Granulocyte Colony-Stimulating Factor Enabled by Isonitrile-Mediated Coupling of Large, Side-Chain-Unprotected Peptides.

Roberts AG, Johnston EV, Shieh JH, Sondey JP, Hendrickson RC, Moore MA, Danishefsky SJ.

J Am Chem Soc. 2015 Oct 14;137(40):13167-75. doi: 10.1021/jacs.5b08754. Epub 2015 Oct 1.

PMID:
26401918
7.

Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.

Danylesko I, Sareli R, Bloom-Varda N, Yerushalmi R, Shem-Tov N, Shimoni A, Nagler A.

Biol Blood Marrow Transplant. 2016 Feb;22(2):277-83. doi: 10.1016/j.bbmt.2015.08.033. Epub 2015 Sep 4.

PMID:
26343949
8.

Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.

Martino M, Recchia AG, Moscato T, Fedele R, Neri S, Gentile M, Alati C, Vincelli ID, Piro E, Penna G, Musolino C, Ronco F, Molica S, Morabito F.

Cytotherapy. 2015 Oct;17(10):1485-93. doi: 10.1016/j.jcyt.2015.05.010. Epub 2015 Jul 15.

PMID:
26188967
9.

Acute myeloid leukemia developing in a granulocyte colony-stimulating factor-mobilized stem cell donor: A case report and review of the literature.

Haddad H, Wungjiranirun M, Gergis U.

Hematol Oncol Stem Cell Ther. 2015 Jul 7. pii: S1658-3876(15)00053-9. doi: 10.1016/j.hemonc.2015.06.001. [Epub ahead of print]

10.

Monitoring Effects of Excipients, Formulation Parameters and Mutations on the High Order Structure of Filgrastim by NMR.

Aubin Y, Hodgson DJ, Thach WB, Gingras G, Sauvé S.

Pharm Res. 2015 Oct;32(10):3365-75. doi: 10.1007/s11095-015-1713-3. Epub 2015 Jun 5.

PMID:
26043856
11.

Pegfilgrastim Improves Survival of Lethally Irradiated Nonhuman Primates.

Hankey KG, Farese AM, Blaauw EC, Gibbs AM, Smith CP, Katz BP, Tong Y, Prado KL, MacVittie TJ.

Radiat Res. 2015 Jun;183(6):643-55. Epub 2015 Jun 2.

PMID:
26035709
12.

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.

Elayan MM, Horowitz JG, Magraner JM, Shaughnessy PJ, Bachier C.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1921-5. doi: 10.1016/j.bbmt.2015.05.024. Epub 2015 May 30.

PMID:
26033279
13.

A thorough QT study to assess the effects of tbo-filgrastim on cardiac repolarization in healthy subjects.

Adar L, Avisar N, Lammerich A, Kleiman RB, Spiegelstein O.

Drug Des Devel Ther. 2015 May 15;9:2653-62. doi: 10.2147/DDDT.S81799. eCollection 2015.

14.

Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor.

Arvedson T, O'Kelly J, Yang BB.

BioDrugs. 2015 Jun;29(3):185-98. doi: 10.1007/s40259-015-0127-4. Review.

15.

Desensitization to lenograstim after a life- threatening reaction to filgrastim.

Nuñez-Acevedo B, Rodríguez-Jiménez B, Domínguez-Ortega J, González-Montellano E, Ibáñez-Heras N, Enrech-Francés S.

J Investig Allergol Clin Immunol. 2015;25(2):158-60. No abstract available.

16.

[Recombinant granulocyte-colony stimulating factor (filgrastim): optimization of conditions of isolation and purification from inclusion body].

Kononova NV, Iakovlev AV, Zhuravko AM, Pankeev NN, Minaev SV, Bobruskin AI, Mart'ianov VA.

Bioorg Khim. 2014 Sep-Oct;40(5):550-9. Russian.

PMID:
25895350
17.

The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy.

Lyman GH, Reiner M, Morrow PK, Crawford J.

Ann Oncol. 2015 Jul;26(7):1452-8. doi: 10.1093/annonc/mdv174. Epub 2015 Apr 7.

PMID:
25851633
18.

Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.

Sörgel F, Schwebig A, Holzmann J, Prasch S, Singh P, Kinzig M.

BioDrugs. 2015 Apr;29(2):123-31. doi: 10.1007/s40259-015-0124-7.

19.

Estimation of pressure-, temperature- and frictional heating-related effects on proteins' retention under ultra-high-pressure liquid chromatographic conditions.

Fekete S, Guillarme D.

J Chromatogr A. 2015 May 8;1393:73-80. doi: 10.1016/j.chroma.2015.03.023. Epub 2015 Mar 17.

PMID:
25823888
20.

An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy.

Zhang W, Jiang Z, Wang L, Li C, Xia J.

Med Oncol. 2015 May;32(5):147. doi: 10.1007/s12032-015-0537-7. Epub 2015 Mar 29.

PMID:
25820754
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk